Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronen Arbel

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Frontiers in Pharmacology|April 3, 2024
Dapagliflozin <i>versus</i> sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fractionRonen Arbel, Abed N Azab, Mansi Oberoi, et al.
Israel Journal of Health Policy Research|June 10, 2025
Primary healthcare delivery adaptations in war-induced population displacementAssi Cicurel, Yael Wolff Sagy, Ilan Feldhamer, et al.
Heart (British Cardiac Society)|April 12, 2019
Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillationRonen Arbel, Ruslan Sergienko, Ariel Hammerman, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 17, 2023
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome AnalysisHilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
JAMA Network Open|July 1, 2026
Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic SurgeryYael Wolff Sagy, Eitan Ernest Winter, Wiessam Abu Ahmad, et al.
Frontiers in Pharmacology|August 21, 2023
Dapagliflozin versus empagliflozin in patients with chronic kidney diseaseHilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
The Lancet. Infectious Diseases|June 23, 2023
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series studyDan Yamin, Matan Yechezkel, Ronen Arbel, et al.
Obesity Facts|May 20, 2026
Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac EventsOrna Reges, Wiessam Abu Ahmad, Noga Oz-Ramot, et al.
The Lancet. Infectious Diseases|April 16, 2023
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort studyRonen Arbel, Alon Peretz, Ruslan Sergienko, et al.
BMJ Open|December 9, 2023
Risk of atrial fibrillation and association with other diseases: protocol of the derivation and international external validation of a prediction model using nationwide population-based electronic health recordsRamesh Nadarajah, Jianhua Wu, Ronen Arbel, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Frontiers in Pharmacology|April 3, 2024
Dapagliflozin <i>versus</i> sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fractionRonen Arbel, Abed N Azab, Mansi Oberoi, et al.
Israel Journal of Health Policy Research|June 10, 2025
Primary healthcare delivery adaptations in war-induced population displacementAssi Cicurel, Yael Wolff Sagy, Ilan Feldhamer, et al.
Heart (British Cardiac Society)|April 12, 2019
Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillationRonen Arbel, Ruslan Sergienko, Ariel Hammerman, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 17, 2023
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome AnalysisHilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
JAMA Network Open|July 1, 2026
Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic SurgeryYael Wolff Sagy, Eitan Ernest Winter, Wiessam Abu Ahmad, et al.
Frontiers in Pharmacology|August 21, 2023
Dapagliflozin versus empagliflozin in patients with chronic kidney diseaseHilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
The Lancet. Infectious Diseases|June 23, 2023
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series studyDan Yamin, Matan Yechezkel, Ronen Arbel, et al.
Obesity Facts|May 20, 2026
Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac EventsOrna Reges, Wiessam Abu Ahmad, Noga Oz-Ramot, et al.
The Lancet. Infectious Diseases|April 16, 2023
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort studyRonen Arbel, Alon Peretz, Ruslan Sergienko, et al.
BMJ Open|December 9, 2023
Risk of atrial fibrillation and association with other diseases: protocol of the derivation and international external validation of a prediction model using nationwide population-based electronic health recordsRamesh Nadarajah, Jianhua Wu, Ronen Arbel, et al.
Pageof 6